Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ALL029
MIFTS: 61

Allergic Disease

Categories: Immune diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Allergic Disease

About this section

MalaCards integrated aliases for Allergic Disease:

Name: Allergic Disease 11 14 75
Hypersensitivity 11 75 43 14 71
Allergic Hypersensitivity Disease 11
Allergic Disposition 71
Allergic Condition 71
Allergic Reaction 71

Classifications:

MalaCards categories:
Anatomical: Immune diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 11 DOID:1205
MeSH 43 D006967
NCIt 49 C3114
SNOMED-CT 68 257550005
UMLS 71 C0020517 C0851444 C1527304 more
Sources

Summaries for Allergic Disease

About this section

Disease Ontology: 11 An immune system disease that is an exaggerated immune response to allergens, such as insect venom, dust mites, pollen, pet dander, drugs or some foods.

MalaCards based summary: Allergic Disease, also known as hypersensitivity, is related to farmer's lung and hypersensitivity reaction type iii disease, and has symptoms including nausea and vomiting, abdominal pain and pruritus. An important gene associated with Allergic Disease is IL5 (Interleukin 5), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Ertapenem and Dapsone have been mentioned in the context of this disorder. Affiliated tissues include skin, t cells and prostate, and related phenotypes are homeostasis/metabolism and immune system

Wikipedia: 75 Hypersensitivity (also called hypersensitivity reaction or intolerance) refers to undesirable reactions... more...
Sources

Related Diseases for Allergic Disease

About this section

Diseases related to Allergic Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 2127)
# Related Disease Score Top Affiliating Genes
1 farmer's lung 32.9 TNF IL2 IGHE CCR6
2 hypersensitivity reaction type iii disease 32.7 TNF IL10 CCR6
3 severe cutaneous adverse reaction 32.7 TNF IFNG CCR6
4 nut allergy 32.7 IL5 IL4 IL13 IGHE CCR6
5 hypersensitivity reaction type iv disease 32.5 TNF IL4 IL2 IL10 IFNG CXCL8
6 drug allergy 32.2 IL5 IL4 IL13 IGHE
7 metal allergy 32.1 TNF IL5 IL4 IL2 IL13 IL10
8 chronic rhinitis 32.1 RNASE3 IL5 IL4 IL13
9 henoch-schoenlein purpura 32.1 TNF RNASE3 CCR6
10 fibromyalgia 32.1 TNF IL4 IL10 CXCL8
11 allergic asthma 32.1 RNASE3 IL9 IL5 IL4 IL3 IL13
12 sarcoidosis 1 32.1 TNF IL9 IL2 IL13 IL10 IFNG
13 pulmonary sarcoidosis 32.1 TNF IL2 IFNG CCL5
14 erythema multiforme 32.0 TNF IL5 IL4 IL2 IL13 IFNG
15 toxicodendron dermatitis 32.0 TNF IL2 CXCL8
16 polycythemia vera 31.9 TNF IL4 IL3 CSF2
17 sympathetic ophthalmia 31.9 TNF IL2 IL10 CCR6
18 churg-strauss syndrome 31.9 TNF RNASE3 IL5 IL3 IL2 IL10
19 autoimmune lymphoproliferative syndrome 31.9 TNF IL2 IL10 CCR6
20 cryoglobulinemia 31.9 TNF IL10 IFNG
21 dermatitis, atopic 31.9 TNF RNASE3 IL9 IL5 IL4 IL3
22 bullous pemphigoid 31.9 TNF RNASE3 IL5 IL4 IGHE FCER2
23 ige responsiveness, atopic 31.8 RNASE3 IL5 IL4 IL13 IL10 IGHE
24 respiratory allergy 31.8 TNF RNASE3 IL9 IL5 IL4 IL3
25 rhinitis 31.7 TNF RNASE3 IL9 IL5 IL4 IL13
26 autoimmune disease of central nervous system 31.7 TNF IL5 IL4 IL2 IL13 IL10
27 dermatitis 31.7 TNF RNASE3 IL5 IL4 IL2 IL13
28 allergic rhinitis 31.6 RNASE3 IL9 IL5 IL4 IL13 IL10
29 interstitial lung disease 31.6 TNF IL4 IL13 IL10 IFNG CXCL8
30 food allergy 31.6 TNF RNASE3 IL9 IL5 IL4 IL13
31 myocarditis 31.4 TNF IL4 IL2 IL10 IFNG CXCL8
32 interstitial lung disease 2 31.4 TNF IL9 IL5 IL4 IL2 IL13
33 childhood-onset asthma 31.4 RNASE3 IL5 IL4 IL13 IL10 IGHE
34 diarrhea 31.3 TNF IL5 IL3 IL2 IL13 IL10
35 purpura 31.3 TNF IL4 IL2 IL10 IFNG CXCL8
36 leprosy 3 31.3 TNF IL5 IL4 IL2 IL13 IL10
37 penicillin allergy 31.3 IL4 IL13 IL10 IGHE IFNG
38 urticaria 31.3 TNF RNASE3 IL5 IL4 IL3 IL13
39 leishmaniasis 31.2 TNF IL5 IL4 IL2 IL13 IL10
40 pneumonia 31.2 TNF IL5 IL4 IL13 IL10 IFNG
41 alopecia 31.2 TNF IL4 IL2 IFNG
42 paine syndrome 31.2 TNF IL10 CXCL8
43 bronchiectasis 31.2 TNF IGHE IFNG CXCL8
44 peripheral nervous system disease 31.2 TNF IL4 IL2 IL10 IFNG CXCL8
45 gastroesophageal reflux 31.2 TNF IL5 IL4 CXCL8 CCR3 CCL11
46 asthma 31.2 TNF RNASE3 IL9 IL5 IL4 IL3
47 schistosomiasis 31.1 TNF RNASE3 IL9 IL5 IL4 IL2
48 headache 31.1 TNF IL2 CXCL8
49 deficiency anemia 31.1 TNF IL3 IL2 IL10 CSF2 CCR6
50 graft-versus-host disease 31.1 TNF IL2 IL10 IFNG

Graphical network of the top 20 diseases related to Allergic Disease:



Diseases related to Allergic Disease
Sources

Symptoms & Phenotypes for Allergic Disease

About this section

UMLS symptoms related to Allergic Disease:


nausea and vomiting; abdominal pain; pruritus; syncope; stridor; tinnitus; snoring; sore throat; exanthema; coughing; vertigo/dizziness; equilibration disorder; signs and symptoms of ill-defined conditions; (non-specific) malaise and fatigue; injection site hypersensitivity; fever of unknown origin

MGI Mouse Phenotypes related to Allergic Disease:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.17 CCR3 CCR6 CSF2 FCER2 HRH4 IFNG
2 immune system MP:0005387 10.11 CCL11 CCL24 CCL5 CCR3 CCR6 CSF2
3 neoplasm MP:0002006 9.95 CSF2 IFNG IL10 IL2 IL3 IL5
4 no phenotypic analysis MP:0003012 9.91 IFNG IGHE IL10 IL13 IL2 IL4
5 digestive/alimentary MP:0005381 9.91 FCER2 IFNG IL10 IL13 IL2 IL4
6 respiratory system MP:0005388 9.73 CCL11 CCL24 CCR3 CSF2 IFNG IL10
7 hematopoietic system MP:0005397 9.58 CCL11 CCL24 CCL5 CCR3 CCR6 CSF2
Sources

Drugs & Therapeutics for Allergic Disease

About this section

Drugs for Allergic Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 720)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ertapenem Approved, Investigational Phase 4 153832-46-3 150610
2
Dapsone Approved, Investigational Phase 4 80-08-0 2955
3
Citalopram Approved Phase 4 59729-32-7, 59729-33-8 2771
4
Empagliflozin Approved Phase 4 864070-44-0 73151030 11949646
5
Linagliptin Approved Phase 4 668270-12-0 57389748 10096344
6
Curcumin Approved, Investigational Phase 4 458-37-7, 84765-67-3 969516
7
Esreboxetine Approved, Experimental, Investigational Phase 4 98769-81-4, 71620-89-8, 98819-76-2 65856
8
Canagliflozin Approved Phase 4 842133-18-0 74323022 24812758
9
Fludrocortisone Approved, Investigational Phase 4 127-31-1 31378
10
Glycerin Approved, Investigational Phase 4 56-81-5 753
11
Sodium fluoride Approved Phase 4 7681-49-4
12
Acetylsalicylic acid Approved, Vet_approved Phase 4 50-78-2 2244
13
Esomeprazole Approved, Investigational, Vet_approved Phase 4 73590-58-6, 119141-88-7 9568614 4594
14
Sorbitol Approved, Investigational Phase 4 69-65-8, 50-70-4 453 6251 5780
15
Abacavir Approved, Investigational Phase 4 136470-78-5, 188062-50-2 441300
16
Montelukast Approved Phase 4 158966-92-8 5281040
17
Ciclesonide Approved, Investigational Phase 4 126544-47-6, 141845-82-1 444033 6918155
18
Capsaicin Approved Phase 4 404-86-4 1548943
19
Cetirizine Approved Phase 4 83881-51-0 2678
20
Dimenhydrinate Approved Phase 4 523-87-5 10660
21 Grape Approved Phase 4
22
Tocopherol Approved, Investigational Phase 4 1406-66-2
23
Thymol Approved Phase 4 89-83-8 6989
24
Fluticasone Approved, Experimental Phase 4 90566-53-3 4659387 5311101
25
Loratadine Approved, Investigational Phase 4 79794-75-5 3957
26
Levocetirizine Approved Phase 4 130018-77-8 1549000
27
Budesonide Approved Phase 4 51333-22-3 5281004 40000 63006
28
Epinastine Approved, Investigational Phase 4 80012-43-7 3241
29
Dapagliflozin Approved Phase 4 461432-26-8 9887712
30
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
31
Hydrogen peroxide Approved, Vet_approved Phase 4 7722-84-1 784
32
Rosiglitazone Approved, Investigational Phase 4 122320-73-4, 155141-29-0 77999
33
Moxifloxacin Approved, Investigational Phase 4 186826-86-8, 354812-41-2, 151096-09-2 152946
34
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
35
Cathine Approved, Experimental, Illicit, Vet_approved, Withdrawn Phase 4 14838-15-4, 492-39-7 131954576 4786 26934
36
Guaifenesin Approved, Investigational, Vet_approved Phase 4 93-14-1 3516
37
Ofloxacin Approved Phase 4 82419-36-1 4583
38
Clarithromycin Approved Phase 4 81103-11-9 84029
39
Metronidazole Approved Phase 4 443-48-1, 69198-10-3 4173
40
Tetracycline Approved, Vet_approved, Withdrawn Phase 4 60-54-8 5353990
41
Simvastatin Approved Phase 4 79902-63-9 54454
42
Ipratropium Approved, Experimental Phase 4 22254-24-6, 60205-81-4 657309 3746
43
Ethinylestradiol Approved Phase 4 57-63-6 5991
44
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
45
Irbesartan Approved, Investigational Phase 4 138402-11-6 3749
46
Adapalene Approved Phase 4 106685-40-9 60164
47
Benzoyl peroxide Approved Phase 4 94-36-0 7187
48
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
49
Polyestradiol phosphate Approved Phase 4 28014-46-2
50
Norgestimate Approved, Investigational Phase 4 35189-28-7 6540478

Interventional clinical trials:

(show top 50) (show all 1819)
# Name Status NCT ID Phase Drugs
1 Cross-reactivity and Tolerability of Ertapenem in Patients With IgE-mediated Allergy to Beta-lactams Unknown status NCT01159379 Phase 4 ertapenem
2 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*1301) for Susceptibility to Dapsone Hypersensitivity Syndrome Unknown status NCT02550080 Phase 4 Dapsone
3 Bacteria and Cytokines as Factors Modulating Visceral Afferent Processing in Irritable Bowel Syndrome: Manipulation of Intestinal Bacteria and Mucosal Cytokines by Probiotic Therapy and the Effect on Visceral Hypersensitivity Unknown status NCT00418340 Phase 4 probiotic (bacterial/dietary supplement)
4 Clinical Efficacy of Giomer Versus Sodium Fluoride Varnish for Management of Hypersensitivity: Randomized Control Trail Unknown status NCT03818945 Phase 4 shofu PRG barrier coat;Sodium fluoride varnish
5 Comparing the Effect of Oral Methyl Prednisolone on Different Radiological Patterns of Hypersensitivity Pneumonitis Unknown status NCT04402177 Phase 4 Methyl Prednisolonate
6 A Placebo-controlled Trial With Citalopram for the Treatment of Typical Reflux Symptoms in Patients With Reflux Hypersensitivity or Functional Heartburn With Incomplete Proton Pump Inhibitor Response Unknown status NCT03499171 Phase 4 Citalopram 20mg;Placebo Oral Tablet
7 Distribution and Expression of Non-neuronal Transient Receptor Potential (TRPV) Ion Channels in Sensitive Skin Syndrome. Unknown status NCT01871883 Phase 4
8 Effect of Oral Supplementation With Curcumin on Insulin Sensitivity in Subjects With Prediabetes Unknown status NCT03917784 Phase 4 Curcumin;Starch
9 A Randomized Double-blind Study to Evaluate the Effect of Linagliptin on Pancreatic Beta Cell Function and Insulin Sensitivity in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy Unknown status NCT02097342 Phase 4 Linagliptin;Placebo;Voglibose
10 The Effects of Xolair (Omalizumab) on Airway Hyperresponsiveness Unknown status NCT00208234 Phase 4 Omalizumab;Placebo for Omalizumab;omalizumab
11 Effect of Escitalopram vs. Reboxetine on Somatic and Visceral Sensitivity of Patients With Major Depressive Disorder: a Randomized, Double Blind Clinical Trial Unknown status NCT00209807 Phase 4 escitalopram;Reboxetine
12 Effects of SGLT2 Inhibitors on Islet Cell Function and Insulin Sensitivity in Patients of Type 2 Diabetes Mellitus Unknown status NCT04014192 Phase 4 Dapagliflozin;Empagliflozin;Canagliflozin
13 Effects of Pioglitazone on Body Composition,Insulin Sensitivity and Protein Metabolism in ESRD Non Diabetic Individuals Unknown status NCT01253928 Phase 4 Pioglitazone
14 Acute Effects of an Oral Fat Load on Skeletal Muscle and Hepatic Insulin Sensitivity (FLAME-study) Unknown status NCT01736202 Phase 4
15 A Double Blind Placebo Controlled Randomised Trial to Study the Effects of Birch Pollen Specific Immunotherapy (BP-SIT) on the Symptoms of the Oral Allergy Syndrome in Adult Patients Unknown status NCT01431859 Phase 4
16 Fludrocortisone's Test in the Identification of Salt Sensitivity Unknown status NCT01453959 Phase 4 Fludrocortisone
17 Basophil Activation Test (BAT) Sensitivity in Child Food Allergy Completed NCT01966640 Phase 4
18 Phase 4 Study to Assess the Safety of Nasal Influenza Immunisation in Egg Allergic Children - a Multicentre Observational Study Completed NCT02111512 Phase 4 Administration of Live attenuated influenza vaccine (LAIV)
19 Integrated Approaches to Food Allergen and Allergy Risk Management: iFAAM: The Impact of Proton-pump Inhibitors (Antacids) on Threshold Dose Distributions Completed NCT02552537 Phase 4 Omeprazole;Placebo
20 Phase 4 Study of Effects of Montelukast Treatment on Allergic Inflammation in Children With and Without Food Allergy, Single Centered, Randomised, Double Blind, Placebo Controlled Parallel Group Cross-over Study Completed NCT01618929 Phase 4 Montelukast
21 Phase 4 Study: Milk Oral Immunotherapy for Cow's Milk Allergy in School-aged Children Completed NCT01361347 Phase 4
22 Inpatient Penicillin Allergy Delabeling Pilot Project at University Hospitals-Rainbow Babies and Children's Hospital in Cleveland, Ohio Completed NCT05020327 Phase 4 Graded Oral Amoxicillin Challenge
23 Short Term Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02773758 Phase 4
24 A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02731833 Phase 4
25 Efficacy and Safety of Danggui-Sayuk-Ga-Osuyu-Saenggang-tang on Korean Patients With Cold Hypersensitivity in the Hands Completed NCT02645916 Phase 4 Danggui-Sayuk-Ga-Osuyu-Saenggang-tang;Placebo: corn starch
26 An 8-Week Clinical Study to Evaluate the Efficacy of Two Oral Hygiene Regimens in the Reduction of Dentin Hypersensitivity After Non-surgical Periodontal Treatment: Randomized Clinical Trial Completed NCT02461030 Phase 4 In-office and at home Colgate sensitive pro-relief - CSPR;In-office Villevie® prophy paste + Colgate Toothpaste
27 The Effect of Toothpastes Containing Ca-hydroxyapatite, Fluoroapatite, and Mg-Zn-hydroxyapatite on Dentin Hypersensitivity: a Randomized Clinical Trial Completed NCT04896294 Phase 4
28 Effect of Korean Red Ginseng on Women With Cold Hypersensitivity of Hands and Feet : a Randomized, Double-blind, Placebo-controlled Trial Completed NCT01664156 Phase 4 Korean red ginseng;Placebo
29 Manipulation of Visceral Hypersensitivity With Probiotic Bacteria in Irritable Bowel Syndrome Completed NCT01139736 Phase 4
30 A Phase IV, Randomised, Multicentre, Double-blind, Study to Evaluate the Clinical Utility of Prospective Genetic Screening (HLA-B*5701) for Susceptibility to Abacavir Hypersensitivity Completed NCT00340080 Phase 4 Abacavir
31 Comparative Study on the Efficacy of OliNano SEAL and Curodont D' Senz in Treatment of Dentin Hypersensitivity Completed NCT05122312 Phase 4 Olinanoseal;Curodont D'senz
32 A Clinical Study Investigating the Efficacy of an Occluding Dentifrice in Providing Relief From Dentinal Hypersensitivity Completed NCT02923895 Phase 4
33 Clinical, Controlled, Double-blind Study on the Effect of Whitening Dentifrices on Tooth Color and Tooth Sensitivity Completed NCT02483013 Phase 4
34 A Double-blind, Double-dummy, Parallel-group, Placebo-controlled, Randomized Study to Assess the Duration of the Suppressive Effects of Desloratadine on the Cutaneous Allergen-induced Wheal and Flare (1) Response After Discontinuation Completed NCT00359138 Phase 4 desloratadine;levocetirizine;Desloratadine placebo tablet;Levocetirizine placebo capsule
35 Evaluating Remineralizers and Desensitizers Agents in Dental Bleaching Treatment: in Vitro and in Vivo Study Completed NCT02316080 Phase 4
36 An Exploratory Clinical Study to Evaluate the Efficacy of Two Currently Marketed Toothpastes Containing Different Concentrations of a Tubule Occlusion Agent Completed NCT01075256 Phase 4
37 An Investigator-initiated Single Center Randomised Clinical Pilot Study to Compare Tolerability of the Sublingual Versus Vestibular Administration Routes for Birch Pollen, Grass Pollen, Ragweed Pollen, or House Dust Mite Allergy Immunotherapy (AIT) Completed NCT05119751 Phase 4 tree 12 SQ-Bet;GRASS 2800 BAU;RAGWEED 12 AMB A 1-U;HDM 12 SQ-HDM
38 Investigating the Efficacy of Artificial Tear Supplements and Cold Compresses for the Treatment of Seasonal Allergic Conjunctivitis Completed NCT01569191 Phase 4 Anti-allergic Medication
39 Effectiveness of Nano-hydroxyapetite Care Paste in Reducing Dentinhypersenstitivity: A Double Blind Randomized Control Trial Completed NCT02936830 Phase 4 5% Sodium Fluoride Varnish;15% Nanohydroxyapetite paste;Glycerol
40 High-sensitivity Cardiac Troponin and CK-MB Concentrations in Patients Undergoing Cardiac Surgery Completed NCT01913873 Phase 4
41 DAPAMAAST: A Double-blind, Randomized, Phase IV, Mechanistic, Placebo-controlled, Cross-over, Single-center Study to Evaluate the Effects of 5 Weeks Dapagliflozin Treatment on Insulin Sensitivity in Skeletal Muscle in Type 2 Diabetes Mellitus Patients. Completed NCT03338855 Phase 4 Dapagliflozin
42 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Sensitivity in Healthy Volunteers: A Randomized, Single-blind, Placebo-controlled Study Completed NCT02674256 Phase 4 CRH
43 The Effect of Intranasal Oxytocin on Pain Sensitivity and Threshold: A Randomized, Double Blinded, Crossover Volunteer Study Completed NCT02550093 Phase 4
44 Insulin Sensitivity After Metformin Suspension in Normal-Weight Women With Polycystic Ovary Syndrome Completed NCT00437333 Phase 4 Metformin cloridrate
45 Randomized, Double-blind, Placebo-controlled Study to Measure 2L®ALERG (Homeopathic Drug) Efficacy on Symptoms of Allergic Rhinitis and Allergic Rhinoconjunctivitis in Patients With a Seasonal Allergy to Grass Pollen Completed NCT02690935 Phase 4 2LALERG;Placebo
46 Effect of Tadalafil on Insulin Secretion and Insulin Sensitivity in Obese Men. Completed NCT02595684 Phase 4 Tadalafil;Placebo
47 A Prospective,Open-label Study of Anastrozole in Post-menopausal Women With Hormone Sensitive Advanced Breast Cancer Completed NCT00544986 Phase 4 Anastrozole
48 Insulin Resistance and Intramyocellular Lipid Content in Glucose Intolerant Subjects Receiving Rosiglitazone Completed NCT00746174 Phase 4 Rosiglitazone;Placebo
49 Combined Bleaching Technique: Efficacy and Tooth Sensitivity - A Randomized, Double Blind Clinical Trial Completed NCT03089216 Phase 4 8% arginine and calcium carbonate
50 Effects of Desensitizing Dentifrices on the Reduction of Pain Sensitivity Caused by In-office Dental Whitening: Double Blind Controlled Clinical Study Completed NCT03019224 Phase 4 Hydrogen peroxide

Search NIH Clinical Center for Allergic Disease

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
prednisolone
prednisolone acetate
PREDNISOLONE ACETATE PWDR
PREDNISOLONE PWDR
Prednisolone sodium phosphate
prednisolone tebutate
Prednisone
PREDNISONE PWDR

Cochrane evidence based reviews: hypersensitivity

Sources

Genetic Tests for Allergic Disease

About this section
Sources

Anatomical Context for Allergic Disease

About this section

Organs/tissues related to Allergic Disease:

MalaCards : Skin, T Cells, Prostate, Lung, Eye, Breast, Skeletal Muscle
Sources

Publications for Allergic Disease

About this section

Articles related to Allergic Disease:

(show top 50) (show all 36359)
# Title Authors PMID Year
1
IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. 53 62
20357258 2010
2
Genetic determinants of both ethanol and acetaldehyde metabolism influence alcohol hypersensitivity and drinking behaviour among Scandinavians. 53 62
20205700 2010
3
Immediate and delayed reactions to radiocontrast media: is there an allergic mechanism? 53 62
19563991 2009
4
Hypersensitivity to proton pump inhibitors: lansoprazole-induced Kounis syndrome. 53 62
18378022 2009
5
Correlation between atopy and hypersensitivity reactions during therapy with three different TNF-alpha blocking agents in rheumatoid arthritis. 53 62
19473578 2009
6
Clinical immunotoxicity of therapeutic proteins. 53 62
19040329 2008
7
CD69 upregulation on T cells as an in vitro marker for delayed-type drug hypersensitivity. 53 62
18005225 2008
8
Hypersensitivity reactions to biological agents with special emphasis on tumor necrosis factor-alpha antagonists. 53 62
17873578 2007
9
[Type IV of hypersensitivity and its subtypes]. 53 62
18409354 2007
10
Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. 53 62
17008937 2006
11
Abacavir hypersensitivity reaction in primary HIV infection. 53 62
16816555 2006
12
T cell-mediated hypersensitivity to quinolones: mechanisms and cross-reactivity. 53 62
16393267 2006
13
[Level of interleukin-12 and interferon gamma in blood serum of children with neoplasms and allergy]. 53 62
16521418 2005
14
Intracellular cytokines may model immunoregulation of abacavir hypersensitivity in HIV-infected subjects. 53 62
15867870 2005
15
The application of a monoclonal antibody to CD62L on paraffin-embedded tissue samples in the assessment of the cutaneous T-cell infiltrates. 53 62
15660650 2005
16
Anti-IgE antibodies for the treatment of asthma. 53 62
15591885 2005
17
Anti-IgE therapy. 53 62
15474858 2004
18
Vaccination with genetically engineered allergens prevents progression of allergic disease. 53 62
15310844 2004
19
Isodon japonicus decreases immediate-type allergic reaction and tumor necrosis factor-alpha production. 53 62
15286441 2004
20
Anti-IgE monoclonal antibody (omalizumab) in the treatment of atopic asthma and allergic respiratory diseases. 53 62
15379589 2004
21
The mast cell: an antenna of the microenvironment that directs the immune response. 53 62
14726495 2004
22
Quantitative assessment of immediate cutaneous hypersensitivity in a mouse model exhibiting an IgE response to Timothy grass allergens. 53 62
14646968 2003
23
Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? 53 62
14677170 2003
24
Hypersensitivity to aldesleukin (interleukin-2 and proleukin) presenting as facial angioedema and erythema. 53 62
12974198 2003
25
Specific delayed-type hypersensitivity responses to ESAT-6 identify tuberculosis-infected cattle. 53 62
12734217 2003
26
Protective effects of a recombinant fragment of human surfactant protein D in a murine model of pulmonary hypersensitivity induced by dust mite allergens. 53 62
12706535 2003
27
L-selectin or ICAM-1 deficiency reduces an immediate-type hypersensitivity response by preventing mast cell recruitment in repeated elicitation of contact hypersensitivity. 53 62
12682269 2003
28
Prevalence of anti-gelatin IgE antibodies in people with anaphylaxis after measles-mumps rubella vaccine in the United States. 53 62
12456938 2002
29
Influence of human T-cell lymphocytotropic virus type 1 infection on serologic and skin tests for strongyloidiasis. 53 62
11716123 2001
30
The role of immunoglobulin E in allergy and asthma. 53 62
11704610 2001
31
Phenotypic characterization of human CD4+ regulatory T cells obtained from cutaneous dinitrochlorobenzene-induced delayed type hypersensitivity reactions. 53 62
11511310 2001
32
TNFalpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients. 53 62
11294926 2001
33
Tumor necrosis factor-alpha promoter polymorphism TNF2 is associated with a stronger delayed-type hypersensitivity reaction in the skin of borderline tuberculoid leprosy patients. 53 62
11261930 2001
34
Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensitivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. 53 62
11085746 2000
35
Expression of IFNgamma, coexpression of TNFalpha and matrix metalloproteinases and apoptosis of T lymphocytes and macrophages in granuloma annulare. 53 62
10994772 2000
36
Unique mechanistic features of allergic rhinitis. 53 62
10856164 2000
37
Regulation of B lymphocyte differentiation. 53 62
10795645 2000
38
Il-4 and IFN-gamma mRNA induction in human peripheral lymphocytes specific for beta-lactam antibiotics in immediate or delayed hypersensitivity reactions. 53 62
10821462 2000
39
Use of alkaline rinsing solution to prevent hypersensitivity reactions during hemodialysis: data from a multicentre retrospective analysis. 53 62
10626828 1999
40
The effects of dexamethasone, cyclosporine, and vitamin D(3) on the activation of dendritic cells stimulated by haptens. 53 62
10552213 1999
41
Targeting Janus kinase 3 in mast cells prevents immediate hypersensitivity reactions and anaphylaxis. 53 62
10480916 1999
42
Activation of the kallikrein-kinin system in hemodialysis: role of membrane electronegativity, blood dilution, and pH. 53 62
10027949 1999
43
Regulation of FcepsilonARI synthesis in human eosinophils. 53 62
10224469 1999
44
Des-Arg9-bradykinin metabolism in patients who presented hypersensitivity reactions during hemodialysis: role of serum ACE and aminopeptidase P. 53 62
10458510 1999
45
Cytokines and allergic diseases: clinical aspects. 53 62
9876771 1998
46
Relationship between helminthic infection and IgE response in atopic and nonatopic children in a tropical environment. 53 62
9500755 1998
47
Role of the monocyte chemoattractant protein and eotaxin subfamily of chemokines in allergic inflammation. 53 62
9365117 1997
48
Increased soluble ICAM-1 concentration and impaired delayed-type hypersensitivity skin tests in patients with chronic liver disease. 53 62
9059357 1997
49
Antiallergic properties of antihistamines. 53 62
8939275 1996
50
An essential role for macrophage migration inhibitory factor in the tuberculin delayed-type hypersensitivity reaction. 53 62
8551232 1996
Sources

Variations for Allergic Disease

About this section
Sources

Expression for Allergic Disease

About this section
Search GEO for disease gene expression data for Allergic Disease.
Sources

Pathways for Allergic Disease

About this section

Pathways related to Allergic Disease according to GeneCards Suite gene sharing:

(show top 50) (show all 61)
# Super pathways Score Top Affiliating Genes
1
Innate Immune System 66
Show member pathways
 14.07 TNF RNASE3 IL9 IL5 IL4 IL3
2
ERK Signaling 64
Show member pathways
 13.93 TNF IL9 IL5 IL4 IL3 IL2
3
Signal Transduction 66
13.87 TNF IL5 IL3 IL2 HRH4 FCER2
4
MIF Mediated Glucocorticoid Regulation 64
Show member pathways
 13.69 TNF IL9 IL5 IL4 IL3 IL2
5
TGF-Beta Pathway 64
Show member pathways
 13.67 TNF IL9 IL5 IL4 IL3 IL2
6
Akt Signaling 64
Show member pathways
 13.54 IL5 IL9 TNF IL4 IL3 IL2
7
Cytokine Signaling in Immune system 66
Show member pathways
 13.46 CCL11 CCL5 CSF2 CXCL8 FCER2 IFNG
8
PAK Pathway 64
Show member pathways
 13.45 CCL11 CCL24 CCL5 CCR3 CCR6 CSF2
9
CCR5 Pathway in Macrophages 64
Show member pathways
 12.97 HRH4 CXCL8 CCR6 CCR3 CCL5 CCL24
10
IL-9 Signaling Pathways 65
Show member pathways
 12.87 TNF IL9 IL4 IL2 FCER2
11
Overview of interferons-mediated signaling pathway 74
Show member pathways
 12.81 CXCL8 IFNG IL10 IL13 IL2 IL3
12
NF-kappaB Signaling 3
12.72 TNF IL4 IL3 IL2 IL10 IFNG
13
Bacterial infections in CF airways 22
Show member pathways
 12.5 TNF IL4 IFNG CXCL8 CCL11
14
Immune response CCR3 signaling in eosinophils 22
Show member pathways
 12.44 CXCL8 CCR3 CCL5 CCL24 CCL11
15
Interleukin-2 family signaling 66
Show member pathways
 12.38 IL9 IL5 IL3 IL2 CSF2
16
Immune response CD16 signaling in NK cells 22
Show member pathways
 12.36 TNF IL4 IL3 IL2 IFNG CSF2
17
T-cell activation SARS-CoV-2 74
Show member pathways
 12.34 CSF2 IFNG IL10 IL2 IL4 IL5
18
Development IGF-1 receptor signaling 22
Show member pathways
 12.29 IL4 IGHE FCER2 CCL11
19
Neuroinflammation and glutamatergic signaling 74
12.23 IFNG IL10 IL13 IL4 TNF
20
Chemokine Superfamily: Human/Mouse Ligand-Receptor Interactions 65
Show member pathways
 12.22 CXCL8 CCR6 CCR3 CCL5 CCL24 CCL11
21
Sudden infant death syndrome (SIDS) susceptibility pathways 74
12.21 TNF IL13 IL10 CXCL8
22
Interleukin-4 and Interleukin-13 signaling 66
12.18 TNF IL4 IL13 IL10 FCER2 CXCL8
23
Spinal cord injury 74
12.14 TNF IL4 IL2 IFNG CXCL8
24
Allograft rejection 74
12.09 CXCL8 IFNG IL10 IL13 IL2 IL4
25
IL27-mediated signaling events 61
Show member pathways
 12.01 TNF IL2 IL10 IFNG
26
Glucocorticoid receptor regulatory network 61
12.01 IL5 IL4 IL2 IL13 IFNG CXCL8
27
CCL18 signaling pathway 74
11.98 CCR3 CCR6 CXCL8 IL10
28
AP-1 transcription factor network 61
11.95 CSF2 CXCL8 IFNG IL10 IL2 IL4
29
Dendritic Cells Developmental Lineage Pathway 65
11.94 TNF IL2 IL10 IFNG CSF2
30
Calcineurin-regulated NFAT-dependent transcription in lymphocytes 61
Show member pathways
 11.94 TNF IL5 IL4 IL3 IL2 IFNG
31
Extrafollicular B cell activation by SARS-CoV-2 74
11.91 IFNG IL10 IL2 IL4 TNF
32
Acute viral myocarditis 74
11.87 IL2 IL10 IFNG CCR3
33
Inflammatory bowel disease signaling 74
Show member pathways
 11.86 TNF IL5 IL4 IL2 IL13 IL10
34
Photodynamic therapy-induced NF-kB survival signaling 74
Show member pathways
 11.85 TNF IL2 IFNG CXCL8 CSF2
35
IL4-mediated signaling events 61
11.83 IL5 IL4 IL10 FCER2 CCL11
36
Innate Lymphoid Cells Differentiation 65
11.81 TNF IL9 IL5 IL4 IL2 IL13
37
Lung fibrosis 74
11.77 TNF IL5 IL4 IL13 CXCL8 CSF2
38
IL3-mediated signaling events 61
Show member pathways
 11.74 IL5 IL3 CSF2
39
Th17 cell differentiation pathway 74
11.74 IL4 IL2 IFNG
40
SARS-CoV-2 innate immunity evasion and cell-specific immune response 74
11.74 CCL5 CSF2 CXCL8 IL10 TNF
41
Interleukin-10 signaling 66
11.74 TNF IL10 FCER2 CXCL8 CSF2 CCL5
42
miRNAs involvement in the immune response in sepsis 74
11.69 TNF IL10 CXCL8
43
THC Differentiation Pathway 64
11.68 TNF IL4 IL2 IL10 IFNG
44
Hematopoietic Stem Cells and Lineage-specific Markers 65
11.67 TNF IL5 IL4 IL3 IL2 IL10
45
Th2 Differentiation 65
11.63 IL9 IL5 IL4 IL2 IL13 IL10
46
Non-genomic actions of 1,25 dihydroxyvitamin D3 74
11.6 CXCL8 IFNG TNF
47
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.58 TNF IL2 IL10 IFNG CSF2
48
Development and heterogeneity of the ILC family 74
11.56 TNF IL9 IL5 IL4 IL13 IFNG
49
Inflammatory response pathway 74
11.5 IFNG IL2 IL4 IL5
50
Interactions of natural killer cells in pancreatic cancer 74
11.4 TNF IFNG CSF2 CCL5
Sources

GO Terms for Allergic Disease

About this section

Cellular components related to Allergic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 10.16 CCL11 CCL24 CCL5 CSF2 CXCL8 FCER2
2 external side of plasma membrane GO:0009897 9.93 TNF IL13 IGHE FCER2 CCR6 CCR3
3 extracellular space GO:0005615 9.83 CCL11 CCL24 CCL5 CSF2 CXCL8 IFNG

Biological processes related to Allergic Disease according to GeneCards Suite gene sharing:

(show all 44)
# Name GO ID Score Top Affiliating Genes
1 G protein-coupled receptor signaling pathway GO:0007186 10.48 CCL11 CCL24 CCL5 CCR3 CCR6 CXCL8
2 positive regulation of gene expression GO:0010628 10.47 TNF IL4 IL13 IFNG CXCL8 CSF2
3 positive regulation of cell population proliferation GO:0008284 10.37 CSF2 IFNG IL2 IL3 IL4 IL5
4 positive regulation of cell migration GO:0030335 10.35 CCL11 CCL24 CCL5 CSF2 IL4
5 signal transduction GO:0007165 10.32 TNF IL9 IL5 IL4 IL3 IL13
6 cellular response to tumor necrosis factor GO:0071356 10.28 CCL11 CCL24 CCL5 CXCL8
7 negative regulation of inflammatory response GO:0050728 10.26 IL4 IL2 IL13 IL10
8 response to virus GO:0009615 10.26 TNF IFNG CCL5 CCL11
9 positive regulation of inflammatory response GO:0050729 10.24 TNF IL2 IFNG CCL24
10 cellular response to type II interferon GO:0071346 10.21 TNF CCL5 CCL24 CCL11
11 calcium-mediated signaling GO:0019722 10.2 TNF CXCL8 CCR6 CCR3
12 neutrophil chemotaxis GO:0030593 10.19 CCL11 CCL24 CCL5 CXCL8
13 cellular response to interleukin-1 GO:0071347 10.19 CCL11 CCL24 CCL5 CXCL8
14 chemotaxis GO:0006935 10.17 CCL11 CCL24 CCL5 CCR3 CCR6 CXCL8
15 regulation of insulin secretion GO:0050796 10.16 TNF IFNG CCL5
16 monocyte chemotaxis GO:0002548 10.16 CCL5 CCL24 CCL11
17 inflammatory response GO:0006954 10.16 CCL11 CCL24 CCL5 CCR3 CXCL8 HRH4
18 positive regulation of endothelial cell proliferation GO:0001938 10.15 IL10 CCR3 CCL24 CCL11
19 chemokine-mediated signaling pathway GO:0070098 10.15 CXCL8 CCR6 CCR3 CCL5 CCL24 CCL11
20 negative regulation of endothelial cell apoptotic process GO:2000352 10.12 IL4 IL13 IL10
21 lymphocyte chemotaxis GO:0048247 10.12 CCL11 CCL24 CCL5
22 positive regulation of B cell proliferation GO:0030890 10.08 IL13 IL2 IL4 IL5
23 positive regulation of receptor signaling pathway via JAK-STAT GO:0046427 10.06 TNF IL5 IL10 CCL5
24 positive regulation of immunoglobulin production GO:0002639 10.03 IL5 IL2 IL13 IL10
25 macrophage activation GO:0042116 10.01 IL4 IL13 CSF2
26 microglial cell activation GO:0001774 10.01 IFNG IL13 IL4 TNF
27 eosinophil chemotaxis GO:0048245 10 CCL11 CCL24 CCL5
28 neuroinflammatory response GO:0150076 9.99 IL4 IFNG
29 positive regulation of MHC class II biosynthetic process GO:0045348 9.99 IL4 IL10 IFNG
30 positive regulation of killing of cells of another organism GO:0051712 9.98 IFNG FCER2
31 positive regulation of humoral immune response mediated by circulating immunoglobulin GO:0002925 9.98 TNF FCER2
32 positive regulation of mononuclear cell migration GO:0071677 9.97 TNF IL4
33 negative regulation of cytokine production involved in immune response GO:0002719 9.97 TNF IL10
34 positive regulation of podosome assembly GO:0071803 9.97 TNF IL5 CSF2
35 regulation of isotype switching GO:0045191 9.95 IL4 IL10
36 positive regulation of cellular biosynthetic process GO:0031328 9.93 CXCL8 CCL5
37 positive regulation of nitrogen compound metabolic process GO:0051173 9.93 IFNG TNF
38 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.92 IFNG TNF
39 positive regulation of plasma cell differentiation GO:1900100 9.92 IL10 IL2
40 negative regulation of complement-dependent cytotoxicity GO:1903660 9.91 IL13 IL4
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.88 TNF IFNG
42 chronic inflammatory response to antigenic stimulus GO:0002439 9.87 TNF IL10
43 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.86 TNF IL4 IL3 IL2 IL13 IFNG
44 immune response GO:0006955 9.75 CCL11 CCL24 CCL5 CCR3 CCR6 CSF2

Molecular functions related to Allergic Disease according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 CCR chemokine receptor binding GO:0048020 9.8 CCL5 CCL24 CCL11
2 growth factor activity GO:0008083 9.8 CSF2 IL10 IL2 IL3 IL4 IL5
3 chemokine activity GO:0008009 9.76 CXCL8 CCL5 CCL24 CCL11
4 cytokine activity GO:0005125 9.7 TNF IL9 IL5 IL4 IL3 IL2
5 CCR3 chemokine receptor binding GO:0031728 9.67 CCL24 CCL11
6 cytokine receptor binding GO:0005126 9.43 IL9 IL4 IL13
Sources

Sources for Allergic Disease

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....